Valeant Pharmaceuticals International Incorporated
VRX:NYSE
| Last | Change / % Change | Dividend Yield | Volume |
| 35.03 | -0.5400 -1.52% | 1.08% | 2,925,273 |
Market data is delayed by at least 20 minutes.
Exclusive Features
When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes.
For full analysis details, Log In with Scottrade or you can:
Latest News Headlines for Valeant Pharmaceuticals International Incorporated
Buyers Accumulate Shares of Valeant Pharmaceuticals International, Up 2% (VRX)
Valeant Pharmaceuticals International (NYSE:VRX) is one of today's notable stocks on the rise, up 2% to $36.23. The S&P; is currently trading 0.9% higher to 1,286 and the Dow Jones Industrial Average is trading 0.9% higher to 11,775.
Valeant Pharmaceuticals to Present at J.P. Morgan 29th Annual Health Care Conference
Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced members of its senior management team will make a presentation at the J.P. Morgan 29th Annual Health Care Conference on Wednesday, January 12, 2011 at 10:30 a.m. PT. The conference will be held at the Westin St. Francis in San Francisco, Calif.
Valeant Pharmaceuticals to Present at J.P. Morgan 29th Annual Health Care Conference
View more recent headlinesValeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced members of its senior management team will make a presentation at the J.P. Morgan 29th Annual Health Care Conference on Wednesday, January 12, 2011 at 10:30 a.m. PT. The conference will be held at the Westin St. Francis in San Francisco, Calif.
Company Background
Valeant Pharmaceuticals International Inc., formerly Biovail Corporation, is a specialty pharmaceutical company. The Company focuses on developing and commercializing products in specialty central nervous system (CNS) disorders. As of December 31, 2009, the Company's products within its development pipeline included Staccato loxapine, Pimavanserin, BVF-018, Fipamezole and GDNF. In May 2009, the Company acquired the United States commercialization rights to Wellbutrin XL from The GlaxoSmithKline Group of Companies (GSK). In June 2009, it acquired the worldwide development and commercialization rights to the entire portfolio of tetrabenazine products, including Xenazine and Nitoman, held by Cambridge Laboratories (Ireland) Ltd. (Cambridge).
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 35.46 | Previous Close 35.57 |
Day High 35.73 | Day Low 34.98 |
52wk High/Date 37.05 / 1/7/2011 | 52wk Low/Date 13.64 / 2/5/2010 |
Beta 0.75 | Market Capitalization 10.34B |
Shares Outstanding 295.31M | Volatility Avg 39.05 |
Avg Vol(10 day) 4.53M | P/E Ratio NM |
EPS (TTM) -0.62 | Annualized Rate -- / -- |
Yield 1.08% | Dividend Announcement 8/5/2010 |
Ex-Date 8/30/2010 | Date of Record 9/1/2010 |
Payable 0.10 - QRTR | Payable Date 10/4/2010 |
Last Trade as of 1/14/2011 4:01 PM ET | |
Exclusive Content
When you open an account with Scottrade, you will get premium content on the News & Content page, including:
- Standard & Poor's News and Commentary
- Dow Jones News
- Briefing News and Commentary
- Market Edge On the Edge Commentary
For full analysis details, Log In with Scottrade or you can:
VRX Valeant Pharmaceuticals International Incorporated vs. Peers
| Peers | |
VRX Valeant Pharmaceuticals International Incorporated | 23.82% |
VRX Valeant Pharmaceuticals International Incorporated | 1.08% |
VRX Valeant Pharmaceuticals International Incorporated | -1.52% |